C. Michael Gibson describes how PCSK9 inhibitors play an essential role in the management of dyslipidemias. According to what is termed the “open microvasculature hypothesis”, he confirms the importance of restoring flow downstream in the capillary bed in heart attack patients.
ESC 2016: dyslipidemias and the “open microvasculature hypothesis”
Dai congressiNewsCARDIOINFO@ESC2016
Scelti dall'editore
- ESC 2016: great expectations
Videointerview with Aldo P. Maggioni, Burkert Pieske, John J.V. McMurray.
- ESC 2016: un update sui NOAC
Intervista a Pasquale PignatelliImportanti aggiornamenti al simposio "Oral anticoagulation, thrombosis and bleeding - improving patient care with NOACs".